Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and pharmacokinetics of atezolizumab with Hu5F9-G4 in relapsed/refractory acute myeloid leukemia; study terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Atezolizumab (atezolizumab)
• Hu5F9-G4 (magrolimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2022-02-21